Keywords: Simeprevir; Oxidative degradation product; Ratio difference; Mean centering; Derivative ratio; Savitsky-Golay filters; Second derivative; Continuous wavelet transform;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Direct-acting antivirals; Hepatitis C; Cirrhosis; Sofosbuvir; Ledipasvir; Paritaprevir; Ombitasvir; Simeprevir;
Keywords: Hepatitis C virus; Liver transplant; Direct-acting antivirals; Recurrent hepatitis C virus; Sofosbuvir; Simeprevir; Ledipasvir; Cholestatic hepatitis;
Keywords: Hepatitis C; Sofosbuvir; Simeprevir; Cost-effectivenessHepatitis C; Sofosbuvir; Simeprevir; Coste-efectividad
Keywords: Hepatitis C virus; Interferons; Ribavirin; Sofosbuvir; Simeprevir
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Keywords: Sofosbuvir; Daclatasvir; Simeprevir; DAA; Sustained virological response;
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals
Keywords: HCV; RASs; DAA; Virologic Treatment Failure; DAA; direct-acting antiviral; DCV; daclatasvir; EOT; end of treatment; GT; genotype; HCV; hepatitis C virus; LDV; ledipasvir; NS; nonstructural protein; PCR; polymerase chain reaction; PEG IFN; pegylated interf
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevirâ±âribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study
Keywords: Sofosbuvir; Simeprevir; HIV/HCV co-infection; Sustained virological response; SVR;
Effectiveness and Tolerability of Direct Acting Antiviral Therapy for Hepatitis C in a Real World Elderly Cohort
Keywords: DAA; direct acting antiviral; HCV; hepatitis C virus; LDV; ledipasvir; RBV; ribavirin; SMV; simeprevir; SOF; sofosbuvir; SVR12; sustained virologic response;
Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations
Keywords: Dermatological side-effects; HCV; Pharmacokinetics; Simeprevir; Therapeutic drug monitoring;
Finally, safe and effective treatment options for hepatitis C in hemodialysis patients
Keywords: HCV; hepatitis C virus; ESRD; end-stage renal disease; HD; hemodialysis; DAA; direct acting antivirals, SOF, sofosbuvir; SIM; simeprevir; LED; ledipasvir; DCV; daclatasvir; RBV; ribavirn; IFN; interferon; SVR; sustained virologic response; pk; pharmacokin
Análisis coste-efectividad del tratamiento de la hepatitis C crónica con sofosbuvir-simeprevir en pacientes con genotipo 1 y fibrosis avanzada
Keywords: Hepatitis C; Sofosbuvir; Simeprevir; Coste-efectividadHepatitis C; Sofosbuvir; Simeprevir; Cost-effectiveness
Development of a simple HPLC–UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma
Keywords: Simeprevir; TMC435; HCV protease inhibitor; Solid-phase extraction; HPLC–UV; Therapeutic drug monitoring
Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy
Keywords: Hepatitis C virus; Protease inhibitor; Real-time PCR; Pegylated interferon; Simeprevir;
Research ArticleDaclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Keywords: HCV; hepatitis C virus; SMV; simeprevir; PegIFN; peginterferon; RBV; ribavirin; DCV; daclatasvir; ASV; asuneprevir; SVR; sustained virologic response; LLOQ; lower limit of quantitation; AE; adverse event; SVR12; sustained virologic response at posttreatme
Research ArticleClinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens
Keywords: SOF; sofosbuvir; CAP/CTM; COBAS AmpliPrep/COBAS TaqMan v2.0; ART; Abbott RealTime HCV test; GT; genotype; RBV; ribavirin; PegIFN; pegylated-interferon alfa; SMV; simeprevir; HCV; hepatitis C virus; SVR; sustained virological response; DAA; direct-acting a
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients
Keywords: Drug resistance assay; Natural polymorphisms; HCV; Q80K; Simeprevir;
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Keywords: HCV; hepatitis C virus; DAA; direct-acting antivirals; SVR; sustained virological response; MELD; model for end-stage liver disease; HCC; hepatocellular carcinoma; BCLC; Barcelona Clinic Liver Cancer group; LOD; limit of detection; EOT; end of treatment;
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis
Keywords: Chronic Hepatitis C; Direct-Acting Antivirals; Decompensation; Safety; CI; confidence interval; CP; Child-Pugh; DAA; direct-acting antiviral; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HR; hazard ratio; MELD; model for end-stage liver diseas
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort
Keywords: Simeprevir; HCV; Protease inhibitor; Prevalence; RAV;
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient
Keywords: DAA; direct-acting antiviral agent; DAD; diffuse alveolar damage; FDA; Food and Drug Administration; HCV; hepatitis C virus; LT; liver transplant; SIM; simeprevir; SOF; sofosbuvir;
Review ArticleInterferon-free therapy for hepatitis C: The hurdles amid a golden era
Keywords: Daclatasvir; Hepatitis C; Interferon; Simeprevir; Sofosbuvir;
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
Keywords: Hepatitis C; Simeprevir; Virology; Q80K polymorphism; Prevalence; NS3/4A protease;
Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK
Keywords: Lineage; NS3; protease inhibitors; Q80K; simeprevir
Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015
Keywords: SOF; Sofosbuvir; DCV; Daclatasvir; RBV; Ribavirin; CP; Child-Pugh; SVR; Sustained virologial response; HVPG; Hepatic venous pressure gradient; G; Genotype; LDV; Ledipasvir; GZR; grazoprevir; EBR; Elbasvir; SMV; Simeprevir; CKD; Chronic kidney disease; RAV
Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update
Keywords: Liver transplantation; HCV; HIV; Coinfection; Direct antiviral agents; DAA; Pegylated-interferon; Ribavirin; Simeprevir; Sofosbuvir; Liver retransplantation; Hepatocellular carcinoma;
Current and Evolving Treatments of Genotype 1 Hepatitis C Virus
Keywords: Hepatitis C; Hepatitis; Sofosbuvir; Simeprevir; Cirrhosis; Ledipasvir antiviral;
Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection
Keywords: HCV; hepatitis C; simeprevir; sofosbuvir;
Determination of simeprevir: A novel, hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography–tandem mass spectrometry
Keywords: LC–MS/MS; Method validation; Antivirals; Hepatitis C; Simeprevir
Journal of Hepatology Update: Hepatitis CAntiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C
Keywords: HCV; hepatitis C virus; PegIFN; pegylated interferon; RBV; ribavirin; SVR; sustained virologic response; DAAs; direct-acting antiviral agents; SOF; sofosbuvir; SIM; simeprevir; FDA; United States Food and Drug Administration; EMA; European Medicines Agenc
Hepatitis C treatment: an incipient therapeutic revolution
Keywords: hepatitis C; pegylated interferon; NS3–4A serine protease inhibitors; direct-acting antivirals (DAAs); sofosbuvir; simeprevir
Review ArticleSofosbuvir as backbone of interferon free treatments
Keywords: DAAs; Daclatasvir; HCV; IFN-free; NS5B nucleotide inhibitors; Ribavirin; Simeprevir; Sofosbuvir;
My Treatment Approach to Chronic Hepatitis CÂ Virus
Keywords: BOC; boceprevir; FDA; Food and Drug Administration; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HIV; human immunodeficiency virus; PEGINF; peginterferon; RBV; ribavirin; RVR; rapid virologic response; SMV; simeprevir; SOF; sofosbuvir; SVR; sust
Review ArticleThe impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
Keywords: Health-related quality of life; Simeprevir; Sofosbuvir;
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Keywords: Direct-Acting Antivirals; Interferon-Free Regimens; Sofosbuvir; Simeprevir; Daclatasvir; DAA; direct-acting antiviral; HCV; hepatitis C virus; HIV; human immunodeficiency virus; HTA; host-targeted agent; IFN; interferon; RdRp; RNA-dependent RNA polymera